The Q3 2026 biotech funding tracker: a rebound that only the rich feel
Biotech venture dollars are up sharply — and almost all of the money went to a handful of AI-shaped names. The gap beneath the megadeals is the real story.
Why Big Pharma is licensing earlier (and paying more)
Seven in ten recent deals happened at preclinical or phase 1 — capturing three quarters of upfront cash. The patent cliff has turned early-stage biology into a seller's market.
The platform premium, audited: what a $200M Series B actually buys
Isomorphic raised $2.1 billion without a marketed product. AI-native biotechs routinely clear nine figures pre-clinic. An audit of what the money purchases — and what evidence would justify it.
